Beyond the Hospital Walls: Optimizing Transitions of Care and Long-Term Management

In ‘Beyond the Hospital Walls: Optimizing Transitions of Care and Long-Term Management,’ our experts delve into the following critical questions:

What are the different classes of therapies that are currently used to prevent recurrent ischemic stroke and how do their respective mechanisms of action target disease pathophysiology?

When a patient gets discharged from the hospital after their first ischemic stroke, how are you currently managing them?

Led by the moderator, the expert neurology experts discuss the distinct pharmacologic mechanisms of DOACs versus antiplatelet therapies and the implementation of structured transitional care programs. Andrew Russman, Danison Emmerson, and David Rose examine the use of Factor Xa inhibitors for cardioembolic stroke and the "NCIS" (non-cardioembolic ischemic stroke) profile, which typically requires antiplatelet monotherapy or short-term DAPT. The panel further details the necessity of the "72-hour touch base" and seven-day follow-up appointments to address hospital readmission factors such as medication access and transportation.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, ‘Future Frontiers in Stroke Care: Biomarkers, Adherence, and Novel Therapies,’ further explores ischemic stroke, highlighting the emerging role of molecular signatures and the unmet need for durable, long-term prevention strategies